S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
TSE:CPH

Cipher Pharmaceuticals - CPH Stock Forecast, Price & News

C$3.35
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
C$3.32
▼
C$3.44
50-Day Range
C$3.34
▼
C$3.87
52-Week Range
C$2.00
▼
C$4.07
Volume
11,350 shs
Average Volume
13,309 shs
Market Capitalization
C$84.02 million
P/E Ratio
7.28
Dividend Yield
N/A
Price Target
N/A

CPH stock logo

About Cipher Pharmaceuticals (TSE:CPH) Stock

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPH Stock News Headlines

March 19, 2023 | seekingalpha.com
Cipher Pharmaceuticals Non-GAAP EPS of -$0.12
March 16, 2023 | finance.yahoo.com
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
March 26, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
March 1, 2023 | finance.yahoo.com
Cipher Pharmaceuticals Announces Closing of New US$35 Million Credit Facility
December 21, 2022 | seekingalpha.com
CPH:CA Cipher Pharmaceuticals Inc.
December 4, 2022 | finance.yahoo.com
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Is Going Strong: Have Financials A Role To Play?
November 13, 2022 | finance.yahoo.com
Cipher Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
September 14, 2022 | baystreet.ca
Signa, Boardwalktech, Cipher at 52-Week Highs
March 26, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
August 5, 2022 | finance.yahoo.com
Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call
June 22, 2022 | finance.yahoo.com
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders and Thanks Director Dr. John Mull
March 17, 2022 | finance.yahoo.com
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
November 11, 2021 | finance.yahoo.com
Cipher Announces Third Quarter and Year-to-Date 2021 Financial Results
November 3, 2021 | finance.yahoo.com
Cipher Pharmaceuticals Schedules Q3 2021 Earnings Release and Conference Call
October 19, 2021 | finance.yahoo.com
Investing in Cipher Pharmaceuticals (TSE:CPH) a year ago would have delivered you a 155% gain
September 8, 2021 | finance.yahoo.com
Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid
August 12, 2021 | finance.yahoo.com
Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica
August 9, 2021 | ca.finance.yahoo.com
Stocks in play: Cipher Pharmaceuticals Inc.
June 23, 2021 | finance.yahoo.com
Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders
May 14, 2021 | markets.businessinsider.com
Cipher Pharmaceuticals Reports First Quarter 2021 Financial Results
May 5, 2021 | finance.yahoo.com
Cipher Pharmaceuticals Schedules Q1 2021 Earnings Release and Conference Call
April 2, 2021 | finance.yahoo.com
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
March 18, 2021 | markets.businessinsider.com
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
January 16, 2021 | benzinga.com
Cipher Pharmaceuticals Receives Arbitration Award on Trulance®
January 7, 2021 | wsj.com
Cipher Pharmaceuticals Inc.
December 3, 2020 | marketwatch.com
Outlook on the Acne Drugs Global Market to 2025 - Impact Analysis of COVID-19
November 10, 2020 | marketwatch.com
Actinic Keratosis Treatment Market Forecast Revised in a New FMI Report as COVID-19 Projected to Hold a Massive Impact on Sales in 2028
See More Headlines
Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CPH Company Calendar

Today
3/26/2023
Next Earnings (Estimated)
5/11/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:CPH
Previous Symbol
TSE:DND
CUSIP
N/A
CIK
N/A
Web
www.cipherpharma.com
Phone
+1-905-6025840
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C$0.46
Trailing P/E Ratio
7.28
Forward P/E Ratio
8.93
P/E Growth
N/A
Net Income
C$26.64 million
Net Margins
128.83%
Pretax Margin
N/A
Return on Equity
51.73%
Return on Assets
11.01%

Debt

Debt-to-Equity Ratio
0.67
Current Ratio
4.07
Quick Ratio
2.67

Sales & Book Value

Annual Sales
C$20.68 million
Price / Sales
4.06
Cash Flow
C$0.95 per share
Price / Cash Flow
3.53
Book Value
C$2.56 per share
Price / Book
1.31

Miscellaneous

Outstanding Shares
25,080,000
Free Float
N/A
Market Cap
C$84.02 million
Optionable
Not Optionable
Beta
1.02

Key Executives

  • Mr. Craig J. Mull
    Interim CEO & Chairman
  • Dr. Diane Gajewczyk
    VP of Scientific & Medical Affairs
  • Mr. Bryan Jacobs
    Chief Financial Officer
  • Mr. Emilio Presti
    Director of Sales, Marketing & Hospital Bus.
  • Chuoru Li
    Corp. Controller
  • David Miller
    Director of Fin.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













CPH Stock - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CPH shares.
View CPH analyst ratings or view top-rated stocks.

How have CPH shares performed in 2023?

Cipher Pharmaceuticals' stock was trading at C$3.84 at the start of the year. Since then, CPH shares have decreased by 12.8% and is now trading at C$3.35.
View the best growth stocks for 2023 here.

When is Cipher Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CPH earnings forecast.

What other stocks do shareholders of Cipher Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB).

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Cipher Pharmaceuticals' stock price today?

One share of CPH stock can currently be purchased for approximately C$3.35.

How much money does Cipher Pharmaceuticals make?

Cipher Pharmaceuticals (TSE:CPH) has a market capitalization of C$84.02 million and generates C$20.68 million in revenue each year. The company earns C$26.64 million in net income (profit) each year or C$0.46 on an earnings per share basis.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The official website for the company is www.cipherpharma.com. The company can be reached via phone at +1-905-6025840.

This page (TSE:CPH) was last updated on 3/26/2023 by MarketBeat.com Staff